Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.58)
# 763
Out of 5,182 analysts
81
Total ratings
54.93%
Success rate
22.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $37 → $34 | $24.28 | +40.03% | 10 | Feb 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $62 → $74 | $55.18 | +34.11% | 3 | Feb 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $475 → $530 | $435.10 | +21.81% | 20 | Jan 23, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $13.35 | -10.11% | 5 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $313.79 | +64.14% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $4.94 | -59.51% | 5 | May 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $40.82 | +10.24% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $8.76 | +36.99% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $3.21 | +55.76% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $43.05 | -18.70% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $405 → $360 | $518.74 | -30.60% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $4.28 | -53.27% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $2.89 | +765.05% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $7.25 | +382.76% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $38.39 | -37.48% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $16.31 | +83.94% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.25 | +135.29% | 1 | Feb 5, 2020 |
Ultragenyx Pharmaceutical
Feb 18, 2026
Maintains: Outperform
Price Target: $37 → $34
Current: $24.28
Upside: +40.03%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Outperform
Price Target: $62 → $74
Current: $55.18
Upside: +34.11%
Vertex Pharmaceuticals
Jan 23, 2026
Maintains: Outperform
Price Target: $475 → $530
Current: $435.10
Upside: +21.81%
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $13.35
Upside: -10.11%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $313.79
Upside: +64.14%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $4.94
Upside: -59.51%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $40.82
Upside: +10.24%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $8.76
Upside: +36.99%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $3.21
Upside: +55.76%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $43.05
Upside: -18.70%
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $518.74
Upside: -30.60%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $4.28
Upside: -53.27%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $2.89
Upside: +765.05%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $7.25
Upside: +382.76%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $38.39
Upside: -37.48%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $16.31
Upside: +83.94%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.25
Upside: +135.29%